Nitrous
Viewing r1 — Apr 26, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Nitrous oxide (N₂O) — laughing gas, whippits, nangs — is a synthetic dissociative of the inorganic gas class. It is the shortest-acting dissociative in common use, with total effects resolving in under five minutes owing to extremely low blood solubility.[1] Nitrous oxide is a non-competitive NMDA receptor antagonist, producing its effects by blocking excitatory signaling and triggering endogenous opioid release for analgesia.[2][3][4]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
First synthesized by Joseph Priestley in 1772, nitrous oxide was introduced as a dental anaesthetic by Horace Wells in 1844 — making it the longest continuously used anaesthetic in medicine.[5] Modern research has repositioned it as a rapid-acting antidepressant, with trials demonstrating significant effects in treatment-resistant depression from a single one-hour inhalation.[6][7] Recreational use expanded substantially via inexpensive cartridges during the 2010s–2020s, prompting the United Kingdom to classify it as a controlled substance in 2023.
Subjective effects include euphoria, anxiolysis, dissociation, auditory distortion, and time alteration. The experience is defined by its compression — the entire arc from onset to baseline collapses into minutes, producing an intense burst of warmth and perceptual dissolution closer to a single flash than the sustained journey of longer-acting dissociatives. Dizziness, disorientation, headache, and nausea are characteristic unsought effects.
Nitrous oxide produces low physical and psychological dependence, though compulsive patterns have been documented with heavy daily use.[8] The primary acute hazard is asphyxiation from oxygen displacement; the dominant chronic risk is spinal cord degeneration caused by irreversible inactivation of vitamin B₁₂, which standard blood tests may fail to detect.[9][10] Over 180 years of clinical use and large-scale safety trials provide a robust evidence base, though tolerance mechanisms and recreational dose-response data remain poorly characterised.
History[edit]
Discovery
Joseph Priestley first synthesized nitrous oxide in 1772 as part of the pneumatic chemistry movement.[5] Humphry Davy, then a young chemist at the Pneumatic Institution in Bristol, undertook systematic self-experimentation in the late 1790s and published his findings in 1800, documenting both the psychotropic and analgesic properties of the gas. Davy noted that N₂O "seems capable of destroying physical pain" and administered it to poets Samuel Taylor Coleridge and Robert Southey, yet neither he nor his contemporaries pursued the surgical application.[5]
Clinical adoption
Four decades passed before Horace Wells, a Hartford dentist, recognised N₂O's anaesthetic potential in 1844 after attending a public demonstration of its intoxicating effects.[5] Wells had a molar extracted under the gas — the first documented surgical use — but a subsequent public demonstration at Harvard was widely considered a failure. Despite this setback, N₂O gained steady acceptance in dentistry through the 1870s and remains a standard anaesthetic today.[5] By the 1930s it had expanded into obstetric pain suppression, formalised with premixed 50% N₂O/O₂ (Entonox) delivery systems.[11]
Modern research and recreational expansion
Interest in NMDA receptor antagonists as rapid-acting antidepressants, following the ketamine paradigm, catalysed a modern research renaissance. Nagele and colleagues conducted the first randomised controlled trial demonstrating rapid antidepressant effects in treatment-resistant depression in 2015,[12] followed by a Phase 2 crossover trial establishing that 25% N₂O matched 50% in efficacy with fewer adverse effects.[6] By 2025, a systematic review had consolidated the antidepressant evidence base.[7] Concurrently, recreational use surged across Europe and the UK driven by cheap culinary-grade cartridges, leading to the United Kingdom's reclassification of N₂O as a Class C controlled substance in November 2023.[13]
The name "laughing gas" dates to Humphry Davy's demonstrations in the 1790s, where subjects frequently burst into laughter — an effect that made the gas a popular attraction at travelling shows and public "frolics" throughout the nineteenth century. The terms "whippits" and "nangs" derive from the small steel cartridges used in whipped cream dispensers, which became the primary delivery format for recreational use.
Chemistry[edit]
Structure
Nitrous oxide is a simple inorganic compound — a linear molecule consisting of two nitrogen atoms and one oxygen atom arranged asymmetrically (N–N–O). It belongs to the nitrogen oxide family but is chemically distinct from nitric oxide (NO) and nitrogen dioxide (NO₂). Unlike virtually all other psychoactive substances, N₂O contains no carbon atoms, functional groups, or ring systems.
The molecule is isoelectronic with carbon dioxide and adopts an analogous linear geometry, though its asymmetric arrangement produces a small permanent dipole moment. The electronic structure features significant resonance delocalisation, with bond lengths intermediate between single and double bonds.
| Molecular formula | N₂O |
| Molecular weight | 44.013 g/mol |
Stereochemistry
As a linear triatomic molecule, N₂O possesses no chirality centres and no stereoisomers.
Physical properties
N₂O is a colourless gas with a faintly sweet odour at room temperature. It is non-flammable but supports combustion at elevated temperatures. The gas liquefies under modest pressure (~50 bar), which explains why small steel cartridges (standard culinary charger: 8 g N₂O) release a large volume of gas upon discharge.
The blood:gas partition coefficient of approximately 0.47 — among the lowest of any inhaled anaesthetic, comparable only to xenon — is the primary determinant of N₂O's extremely rapid onset and offset.[1] Blood and brain concentrations equilibrate within seconds of inhalation.
Pharmacology[edit]
Mechanism of action
N₂O produces its characteristic combination of dissociation, analgesia, anxiolysis, and euphoria through multiple parallel mechanisms. No single receptor target accounts for the full effect profile.
NMDA receptor antagonism
The primary mechanism is non-competitive blockade of NMDA receptors, acting as an open-channel blocker. Genetic evidence in C. elegans confirmed that the NMDA receptor subunit NMR-1 is required for N₂O's behavioural effects.[14] N₂O binds at a site mechanistically distinct from other volatile anaesthetics — mutations that abolish the effects of most anaesthetics leave N₂O inhibition intact.[2] Crystallographic work shows it occupies hydrophobic cavities within protein monomers, separate from the ketamine/ethanol binding pocket.[15]
Because N₂O is a gas, its potency is expressed as minimum alveolar concentration (MAC) rather than the nanomolar binding affinities used for conventional drugs. No Ki or IC₅₀ values at the NMDA receptor have been published.
Endogenous opioid release
Analgesia is mediated through stimulation of endogenous opioid peptide release. The primary mediating peptide is dynorphin, acting at kappa opioid receptors — μ-opioid knockout mice retain normal N₂O analgesia, confirming the kappa pathway as the functional effector.[3][4] N₂O also increases β-endorphins levels in pain-related brain regions via a nitric oxide-dependent mechanism.[16]
Noradrenergic pathway
N₂O activates noradrenergic neurons in pontine brainstem nuclei, increasing norepinephrine release into the spinal cord. This pathway is required for N₂O's analgesic effects but not its sedative effects — a critical mechanistic dissociation.[17] The specific receptor subtype mediating spinal analgesia is the alpha₂B adrenoceptor.[17]
Additional mechanisms
Anxiolysis may involve GABA-A modulation, producing effects analogous to benzodiazepines, though this mechanism remains less well characterised.[18] Additional analgesic targets include activation of TREK-1 potassium channels on sensory neurons and blockade of voltage-dependent calcium channels.[19]
A recently identified mechanism — inhibition of SK2 potassium channels — activates Layer 5 pyramidal neurons in the cingulate cortex independently of NMDA receptors and appears to be both necessary and sufficient for antidepressant-like effects in rodent models.[20] N₂O also produces Ketamine-like enhancement of excitatory glutamate transmission in the hippocampus, consistent with NMDA antagonism-mediated disinhibition of glutamatergic circuits.[21]
Pharmacokinetics
N₂O is administered exclusively by inhalation. Pulmonary absorption is extremely rapid, driven by the exceptionally low blood:gas partition coefficient of approximately 0.47.[1] Clinical onset occurs within 5–10 seconds; effects resolve within 1–5 minutes of cessation.
The gas distributes rapidly across all tissue compartments with high brain penetration. It undergoes virtually no metabolism — it is not processed by liver enzymes — and greater than 99% of the administered dose is exhaled unchanged.[22]
N₂O cannot produce full surgical anaesthesia as a sole agent at normal atmospheric pressure, as its MAC of 1.04 atm exceeds one atmosphere.[23] At hyperbaric concentrations (1.55 atm), it produces muscle rigidity, laboured breathing, and heavy sweating.[23]
Upon abrupt cessation, N₂O diffuses rapidly from blood back into the lungs, transiently diluting alveolar oxygen — a phenomenon called diffusion hypoxia that requires supplemental oxygen for 2–5 minutes in clinical settings.[1] Published human pharmacokinetic parameters at recreational doses are absent from the literature; N₂O is extremely difficult to measure in biological samples, which is why indirect biomarkers — vitamin B₁₂, homocysteine, and methylmalonic acid — are used for diagnostic purposes.[22]
Neuroscience[edit]
Where it acts
As an NMDA receptor antagonist, N₂O disrupts communication between cortical and subcortical brain regions. Blockade of NMDA receptors on inhibitory interneurons paradoxically increases cortical excitability while disrupting the coordinated oscillations that underpin normal conscious processing — producing dissociation, derealization, and time alteration without loss of consciousness at sub-anaesthetic concentrations.
In parallel, N₂O engages a descending pain control system originating in pontine brainstem nuclei. Norepinephrine release into the spinal cord suppresses pain signaling at the spinal level,[17] operating independently of the supraspinal dynorphin/kappa opioid pathway[24] — a dual analgesic architecture unique among dissociatives.
Why it matters
The dominant framework for N₂O's antidepressant effects follows the glutamate hypothesis: NMDA blockade triggers a surge of excitatory glutamate signaling that promotes the formation of new synaptic connections in prefrontal and hippocampal circuits.[25] Functional neuroimaging has shown that a single inhalation produces persistent increases in global brain connectivity — particularly in visual cortex and the dorsal attention network — lasting more than 24 hours,[26] mirroring the antidepressant response window.
The 2025 discovery that N₂O also activates cortical neurons via SK2 potassium channel inhibition, independently of NMDA receptors,[20] suggests a dual-mechanism model. This may explain why 25% N₂O — a concentration producing relatively modest NMDA blockade — matches 50% in antidepressant efficacy.
Key unresolved questions include whether the 25% concentration that matches 50% in antidepressant efficacy also produces equivalent neuroplastic changes — existing connectivity data used a single concentration.[26] The relative contributions of SK2 channel inhibition versus NMDA antagonism in humans remain unknown, as the SK2 data derive from rodent models.[20]
Subjective Effects[edit]
N₂O delivers an experience defined by its extreme brevity. The entire arc — from first inhalation through peak to baseline — compresses into minutes, producing a concentrated burst of euphoria, warmth, and perceptual dissolution. At lower concentrations the effects are anxiolytic and gently dissociative; at higher concentrations, pronounced derealization, auditory distortion, and transient amnesia emerge. Because the window is so narrow, the experience is almost entirely shaped by the seconds surrounding inhalation: body position, oxygen availability, sensory environment (particularly music), and whether the gas is self-titrated from a balloon or inhaled from a continuous source.
Among dissociatives, N₂O is most often compared to ketamine for their shared NMDA antagonism, but the experiential profiles diverge sharply. Where ketamine offers a gradual, immersive dissociative journey lasting an hour or more, N₂O delivers a compressed flash — closer in character to a single deep breath of something overwhelming than to the sustained architecture of a ketamine experience.
Effect Grid
At common doses (8–16 g inhaled, one to two standard cartridges), the full characteristic N₂O experience manifests: pronounced euphoria, dissociation from the immediate environment, and significant time distortion — seconds may feel stretched or compressed. Auditory distortions are common, including a characteristic oscillating or "wah-wah" quality to sounds. Mild geometric visual disturbances and a strong sense of bodily lightness or floating emerge.
Physically, dizziness is pronounced and motor control is substantially impaired — remaining seated is essential. Anxiety suppression is strong. Cognitive impairment is moderate, with slowed processing and impaired short-term memory. The peak lasts 15–30 seconds, with full resolution within 1–5 minutes.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Touch suppression · Depth perception distortion · Perspective distortion · Visual acuity suppression · Visual haze / noise · Geometry · Synesthesia · Visual processing suppression · Internal hallucinations · External hallucinations
Visual haze / noise · Geometry · Synesthesia · Visual processing suppression · Internal hallucinations · External hallucinations
Body high · Pain suppression · Vibrations / buzzing · Tactile euphoria · Breathing alteration · Laughter fits · Sedation · Body schema distortion · Muscle relaxation · Headache · Nystagmus (eye wobbles) · Physical fatigue · Nausea · Heart rate perception changes · Vomiting · Bodily dissociation
Breathing alteration · Laughter fits · Sedation · Body schema distortion · Muscle relaxation · Headache · Nystagmus (eye wobbles) · Physical fatigue · Nausea · Heart rate perception changes · Vomiting · Bodily dissociation
Memory suppression · Thought deceleration · Confusion · Focus suppression · Information processing suppression · Humor enhancement · Pattern recognition suppression · Suggestibility enhancement · Thought disorganization · Thought loops · Language suppression · Memory fragmentation · Amnesia
Focus suppression · Information processing suppression · Humor enhancement · Pattern recognition suppression · Thought disorganization · Thought loops · Language suppression · Memory fragmentation · Amnesia
Sociability enhancement · Craving · Cognitive disconnection
Timeline
First perceptible effects within seconds of inhalation — a faint light-headedness and warmth signal the gas reaching the CNS.
Rapid intensification over seconds. Euphoria, tingling, and auditory changes build quickly as blood-brain equilibration completes.
Maximum dissociation, euphoria, and perceptual distortion. Time distortion is most pronounced. Motor control is impaired; remain seated.
Effects fade rapidly as N₂O is exhaled. Cognitive clarity returns within 1–3 minutes. Mild residual dizziness and warmth may persist briefly.
Subtle residual mood elevation and mild light-headedness. Cognitive function returns to near-baseline within minutes.
⚠ Do not drive or operate machinery for at least 15 minutes after last inhalation, as residual dizziness and impaired coordination may persist.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- High
- Withdrawal
- None
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Negligible
- Psychological
- Low
- Compulsive redosing
- Moderate
- Dose escalation
- Low
- Cross-tol.
- —
Toxicity
Acute toxicity
No lethal dose (LD₅₀) has been established for N₂O in humans. The gas is not directly toxic to cells at any achievable concentration; the primary acute lethal mechanism is asphyxiation from oxygen displacement.[27] Inhalation of pure N₂O without supplemental oxygen produces loss of consciousness within seconds. Deaths have been attributed to positional suffocation (head inside a bag or fixed to a delivery source) or falls following fainting.
Diffusion hypoxia — a transient drop in oxygen levels as N₂O rapidly floods back from blood into the lungs upon cessation — is an additional acute risk managed in clinical settings with 2–5 minutes of supplemental oxygen.[1]
Chronic neurotoxicity: B₁₂ inactivation
The most serious consequence of repeated N₂O use is subacute combined degeneration of the spinal cord. N₂O irreversibly destroys the function of vitamin B₁₂ (cobalamin) by oxidising its cobalt ion, disabling two enzymes essential for myelin production and energy metabolism.[28]
N₂O causes functional inactivation of B₁₂ rather than true deficiency. Standard serum B₁₂ blood tests may return normal results even with clinically significant nerve damage.[10] Diagnosis requires measurement of homocysteine and methylmalonic acid (MMA).
A systematic review of 100 patients found the following prevalence of symptoms and findings[9]:
| Finding | Prevalence |
|---|---|
| Tingling and numbness | 80% |
| Unsteady gait | 58% |
| Weakness | 43% |
| Spinal cord degeneration | 28% |
| Nerve damage visible on MRI | 68% |
| Elevated homocysteine | 90.3% |
| Elevated MMA | 93.8% |
Median patient age was 27 years; 57% were recreational users. The characteristic MRI finding is an inverted "V-sign" on cervical spine imaging.[29]
Nerve testing suggests N₂O causes unique nerve damage distinct from ordinary B₁₂ deficiency — direct toxic effects on nerve fibres beyond the metabolic pathway.[30]
B₁₂ supplementation alone does not protect against spinal cord degeneration if N₂O use continues. Cases of degeneration occurring despite supplementation have been documented.[31] Cessation of use is required.
Early treatment (stopping use plus B₁₂ replacement) usually produces gradual improvement, but recovery may take months and many patients retain residual symptoms. Irreversible nerve damage can occur with prolonged heavy use.[8]
Blood toxicity
Prolonged continuous exposure (>12–24 hours) produces abnormal blood cell formation.[32] Exposure under 6 hours causes no blood abnormality; 12–24 hours of continuous exposure causes changes that reverse within 12 hours of stopping.[33]
Cardiovascular effects
Elevated homocysteine from B₁₂ inactivation is a recognised risk factor for blood clots.[22] However, the ENIGMA-II trial (n = 7,112) found no increase in cardiovascular death or major cardiovascular events at one year in surgical patients.[34]
Occupational exposure
Chronic occupational exposure in unscavenged medical settings is linked to reproductive harm in animal studies at concentrations ≥1,000 ppm.[35] Workplace scavenging systems and exposure limits are recommended.[1]
Psychological Risks
Acute psychological effects at recreational doses are generally mild and resolve within minutes: transient anxiety, dizziness, disorientation, and confusion.
Prolonged heavy use has been associated with psychosis and delirium, particularly in the context of concurrent B₁₂ deficiency.[36] A proposed mechanism links chronic N₂O use to psychosis through elevated homocysteine levels disrupting NMDA function[37] — the same metabolic disruption that damages myelin also alters brain signaling.
No data exist on persistent perceptual changes (HPPD) following N₂O use. The dissociative rather than serotonergic mechanism makes this unlikely.
Tolerance & Dependence
Physical dependence liability is low. No formal withdrawal has been identified for N₂O. Psychological dependence liability is also rated low, though cases of compulsive use with heavy daily frequency (>10 sessions per day) have been documented.[8]
Two candidate reinforcement mechanisms have been identified: endogenous opioid release providing direct positive reinforcement, and dopamine release via NMDA antagonism of inhibitory pathways, analogous to the mechanism proposed for ketamine and PCP.[8] A narrative review using diagnostic criteria confirmed N₂O dependence risk.[38]
Survey data found that some recreational users reported >20 occasions of past-year use, with a minority exhibiting patterns consistent with problematic use.[39] No published data exist on cross-tolerance between N₂O and other NMDA antagonists at recreational doses. The seed tolerance values (half-life: 5 days; full reset: 1.5 weeks) lack verification in published literature.citation needed
Drug Interactions
N₂O's interaction potential through liver metabolism is negligible — it is not processed by liver enzymes and does not affect the metabolism of other drugs.
Interactions are pharmacodynamic, centring on additive depressant effects. N₂O is routinely co-administered with opioids in clinical anaesthesia, where it reduces the dose requirements of co-administered drugs.[18] At recreational doses, combining N₂O's endogenous opioid release with external opioid use carries theoretical risk of additive respiratory depression, though N₂O's indirect opioid mechanism and extremely rapid elimination alter the risk profile. No dose-response or safety studies exist for recreational N₂O plus opioid combinations.
Combinations with other depressants (alcohol, GHB/GBL, benzodiazepines) carry expected additive sedation, impaired coordination, and increased oxygen deprivation risk. N₂O has no serotonergic mechanism; serotonin syndrome risk is not established.
Contraindications
Vitamin B₁₂ deficiency or disorders of B₁₂ metabolism — including pernicious anaemia, strict vegan diets with inadequate supplementation, and absorption disorders — is an absolute contraindication. Pre-existing B₁₂ depletion dramatically accelerates the onset of spinal cord degeneration upon N₂O exposure.[1][40]
Closed gas-containing body cavities — collapsed lung, bowel obstruction, middle ear disease, or recent eye surgery involving gas — are absolute contraindications. N₂O diffuses into gas-filled spaces approximately 34 times faster than nitrogen diffuses out, dangerously expanding cavity pressure.[11][1]
Pre-existing nerve damage or spinal cord disease is a relative contraindication, as B₁₂ inactivation may accelerate neurological decline.
First trimester of pregnancy is a relative contraindication based on animal data showing reproductive harm at prolonged exposures.[35][40]
Harm Reduction[edit]
Forms & Identification
N₂O is most commonly encountered as gas discharged from small steel cartridges (8 g "whippits" or "nangs") into balloons, or from larger medical and catering cylinders. Because the gas itself is colourless and nearly odourless, there is no visual or olfactory way to distinguish N₂O from other compressed gases.
The primary identification concern is not adulteration but delivery method. Gas inhaled directly from a pressurised source risks cold burns to the mouth, throat, and lungs, and eliminates the self-limiting oxygen mixing that a balloon provides. Cartridges marketed as food-grade and medical-grade contain the same compound; there is no meaningful purity distinction for the end user.
Guidelines
- Always inhale from a balloon, never directly from a cartridge or pressurised tank — the balloon acts as a volume limiter and allows air mixing between breaths
- Maintain adequate oxygen supply: breathe normal air between inhalations and do not hold breaths for extended periods
- Use in a seated position on a soft surface to reduce fall and head injury risk
- Do not place bags, masks, or any enclosure over the head — this is the primary mechanism of N₂O-related death
- Space sessions by several minutes to allow oxygen levels to normalise between uses
- Do not use alone at high doses — impaired consciousness may prevent self-rescue from oxygen deprivation
- Anyone using N₂O regularly (weekly or more) should supplement with vitamin B₁₂ and consider periodic homocysteine and MMA blood testing — noting that supplementation does not eliminate risk if use continues[31]
- Numbness, tingling, or difficulty walking after a period of regular use are warning signs of nerve damage requiring immediate medical attention and cessation of use
Set & Setting
N₂O's extremely short duration means that set and setting operate differently than for longer-acting substances. The entire experience occurs in the posture and environment present at the moment of inhalation — there is no time to adjust.
Seated positions are strongly preferred; standing increases fall risk during the brief period of impaired coordination. Music and ambient sound heavily modulate the qualitative character of the experience. A sober companion is advisable when using higher concentrations or repeated doses, particularly because oxygen deprivation may not be self-perceived.
Aftercare & integration. N₂O's brief duration means the aftercare window is short. Most users return to baseline within 5 minutes and require no specific recovery period. Mild headache, dizziness, or fatigue may persist for 15–30 minutes after heavy sessions.
For those using N₂O for its dissociative or introspective qualities, the experience can be surprisingly vivid despite its brevity. Noting impressions immediately after — before the rapid return to baseline overwrites them — is helpful for those seeking to integrate insights. After sessions involving repeated dosing, fresh air and hydration support recovery. Anyone who experiences persistent tingling, numbness, or unsteadiness should seek medical evaluation promptly.
Recovery & Support
While N₂O dependence is uncommon, compulsive use patterns can develop — particularly with easy access to large quantities. Warning signs include daily use, escalating consumption (tens or hundreds of cartridges per session), and continued use despite neurological symptoms.
For those seeking to reduce or stop heavy use, the short duration and absence of physical withdrawal mean that cessation does not require medical detoxification. The challenge is typically behavioural: breaking the pattern of compulsive re-dosing. Standard substance use support resources — counselling, peer support groups, and structured harm reduction programmes — are appropriate. Anyone with neurological symptoms should prioritise medical evaluation; B₁₂ replacement therapy is standard treatment, and nerve recovery can take months.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
The critical distinction is between normal N₂O effects (brief dizziness, euphoria, disorientation resolving within minutes) and oxygen deprivation (blue or grey lips, loss of consciousness, seizure, failure to resume normal breathing after stopping inhalation). Any loss of consciousness lasting more than 30 seconds, any seizure, or any blue discolouration of the lips or fingernails requires emergency response.
Immediate steps:
- 1. Stop all N₂O administration immediately
- 2. Move the person to fresh air and ensure a clear airway
- 3. If unconscious but breathing, place in the recovery position
- 4. If not breathing, begin rescue breathing or CPR
- 5. Call emergency services if the person does not regain consciousness within 60 seconds, has a seizure, or shows signs of oxygen deprivation
What to tell the dispatcher: State that the person inhaled nitrous oxide, approximately how much (number of cartridges or duration of use), when they became unresponsive, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
For suspected nerve damage (tingling, numbness, difficulty walking after repeated use over days or weeks): this is not an acute emergency but requires urgent medical evaluation. Request homocysteine and MMA blood tests — standard B₁₂ levels may appear normal.[10]
Legal Status[edit]
N₂O is not scheduled under any United Nations drug convention — neither the 1961 Single Convention on Narcotic Drugs, the 1971 Convention on Psychotropic Substances, nor the 1988 Convention Against Illicit Traffic.[41] Its dual status as an essential medical agent, a food-grade propellant (E942), and a potent greenhouse gas creates regulatory complexity that most jurisdictions are only beginning to address.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not federally scheduled | FDA-regulated as food additive; no federal scheduling under the Controlled Substances Act. Several states restrict sale to minors or sale with intent to inhale[41] |
| United Kingdom | Class C (Misuse of Drugs Act 1971), Schedule 5 | Reclassified November 2023. Possession or supply for non-medical inhalation is illegal. Medical and dental use preserved[13] |
| Australia | State-by-state regulation | Victoria: Schedule 6 poison for non-therapeutic use. South Australia: age restriction and time-of-sale restriction. NSW: reform consultation underway[41] |
| France | Restricted sale | 2023 decree limiting individual sale to cartridges ≤8.6 g in boxes of ≤10citation needed |
| European Union | Under review | EU Commission considering harmonised classification as reproductive toxicant (2024)citation needed |
| Belgium / Netherlands | National restrictions | Various restrictions on large-format tanks popular for recreational use[41] |
| Canada | Not federally scheduled | Health Canada has issued recalls of N₂O chargers marketed for inhalation without authorisation[41] |
The global regulatory trend is toward increasing restriction, driven by rising recreational use and documented neurological harms, while preserving access for legitimate medical, dental, and food-industry applications. N₂O's status as a greenhouse gas approximately 300 times more potent than CO₂ adds an environmental policy dimension absent from other controlled substance debates.[1]
references
- [1]
- [2] ^abOgata J et al. (2006) Effects of anesthetics on mutant N-methyl-D-aspartate receptors expressed in Xenopus oocytes — Journal of pharmacology and experimental therapeutics PMID:16622040
- [3] ^abBranda EM, Ramza JT, Cahill FJ, Tseng LF, Quock RM (2000) Role of brain dynorphin in nitrous oxide antinociception in mice — Pharmacology, biochemistry, and behavior PMID:10672972
- [4] ^abKoyama T et al. (2009) Deletion of mu-opioid receptor in mice does not affect the minimum alveolar concentration of volatile anaesthetics and nitrous oxide-induced analgesia — British Journal of Anaesthesia doi:10.1093/bja/aep246
- [5]
- [6] ^abNagele P et al. (2021) A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression — Science Translational Medicine doi:10.1126/scitranslmed.abe1376